Podcasts about bll

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

In November 2019, hikers traveling through a remote mountain region in British Columbia discovered a burned-out truck abandoned on a rugged forest trail. The area lies deep within the Tolkien Range, far away from any roads and even farther from the life of the man who owned the vehicle. The truck belonged to 26-year-old IT student Marshal Iwaasa, who had last been seen nearly 700 miles away in Alberta. How his truck ended up there and what happened to him remains a mystery. Just days later, another man, Daniel Reock, disappeared under strange circumstances not far from the same region. Are these two cases connected, or is it a chilling coincidence? Join Cam and Jen as they discuss '700 Miles to Nowhere: Marshal Iwassa.' If You Have Information Marshal Iwaasa 5'11", approximately 170 lbs Brown eyes, curly brown hair Distinct tattoos Last seen wearing red high-top sneakers, a green hoodie, a gray knit hat, and black denim pants Driving a blue 2009 GMC Sierra (Alberta plate BLL-1099) If you have information about Marshal's disappearance, contact: Lethbridge Police Service: 403-328-4444 Crime Stoppers: 1-800-222-8477 or p3tips.com Case #19030078 Daniel Reock If you have information regarding Daniel's disappearance, contact: Squamish RCMP: 604-892-6100 Crime Stoppers: 1-800-222-8477File #2020-121 A huge Thank You to our team: Listener Discretion by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Edward October ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Research & Writing by Lauretta Allen Executive Producers Nico & Jesse of The Inky Pawprint ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://theinkypawprint.com⁠⁠⁠⁠⁠ Sources: https://www.youtube.com/watch?v=G9tbUSK__3M  https://www.youtube.com/watch?v=2Yueni460aM https://en.wikipedia.org/wiki/Disappearance_of_Marshal_Iwaasa https://www.youtube.com/watch?v=SHJ5t0YLASY&t=1s https://www.newspapers.com/image/619970689/?match=1&terms=Iwaasa https://www.newspapers.com/image/680176348/?match=1&terms=Iwaasa https://www.newspapers.com/image/616734014/?match=1&terms=Marshal%20Iwaasa https://www.newspapers.com/image/616731902/?match=1&terms=Marshal%20Iwaasa https://www.canadaunsolved.com/cases/tag/Marshal+Iwaasa+missing https://www.newspapers.com/image/913493820/?match=1&terms=Marshal%20Iwaasa https://www.ucfiles.com/CA/104200185.php https://www.cbc.ca/news/canada/british-columbia/6-men-missing-in-same-region-of-b-c-s-southern-interior-but-no-links-in-cases-police-say-1.5702425 https://www.mountaineers.org/activities/routes-places/brian-waddington-hut https://www.doenetwork.org/cases/6248dmab.html https://www.piquenewsmagazine.com/cover-stories/findmarshy-8906288 https://mysteriesofcanada.com/bc/the-british-columbia-triangle-6-6-canadian-manhunts-2019/ https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5947a2.htm https://www.fbi.gov/contact-us/field-offices/losangeles/news/former-olympian-added-to-fbis-list-of-ten-most-wanted-fugitives https://en.wikipedia.org/wiki/Ryan_Wedding https://www.squamishchief.com/local-news/squamish-vigil-aims-to-keep-daniel-reochs-memory-alive-7837653 https://www.princegeorgecitizen.com/local-news/dead-surrey-man-had-crime-related-link-to-prince-george-3737747 Learn more about your ad choices. Visit megaphone.fm/adchoices

Im Kanton Aargau steigt die Zahl der Personenwagen an: Im Kanton fuhren Ende September über 617'000 Fahrzeuge. Das sind gut 8000 Fahrzeuge mehr als vor einem Jahr, ein Plus von 1.3 Prozent. Das zeigt die neuste Statistik des Kantons. Die meisten Autos fahren nach wie vor mit Benzin oder Diesel. Weitere Themen in der Sendung: · Verhandlung am Bezirksgericht Lenzburg: ein Mann soll seine Ehefrau 2023 getötet haben. Er gibt die Tat zu. Die Verhandlung läuft, wann ein Urteil erwartet werden kann, ist noch nicht klar. · Hausdurchsuchung in Lenzburg: Eine Tonne Schmuggel-Fleisch, 6000 Hanfpflanzen und 180 Kilogramm THC-haltige Bllüten wurden sichergestellt.

19th May: Blockchain DXB podcast

It's estimated that 93% of Americans are metabolically unhealthy. These individuals have what's called insulin resistance. A better description is hyperinsulinemia. When you have chronically high levels of insulin, you are going to store fat and build disease. I'm going to share with you a 5 step protocol to reverse insulin resistance once and for all! Your first step is to replace insulin producing foods with foods that lower insulin. This leads us to looking at macronutrients. We have 3 macros, carbohydrates, protein, and fat. As you see on the chart, carbohydrates will produce the MOST insulin inside your body. The second method to reverse insulin resistance is eliminate snacking and practice time restricted feeding… The third way to reverse insulin resistance is with block fasting. The fourth way to reverse insulin resistance is to build lean muscle. The fifth way to reverse insulin resistance is to reduce your toxic load. Resources Mentioned: Reverse Your Insulin Resistance & Diabetes. Free Training: http://www.diabetesmethod.com  My favorite olive oil: http://www.ketokampoliveoil.com Wild Pastures GrassFed Meat & Wild Caught Seafood: http://www.ketokampmeat.com Studies: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140086/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073199/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215354/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211326/ https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005258 https://www.mdpi.com/2072-6643/11/2/357 https://pubs.rsc.org/en/content/articlelanding/2018/fo/c8fo00194d https://www.mdpi.com/2072-6643/11/2/357 https://bit.ly/3B8l0Qs https://cayeit.com/health-effects-ghee-analysis/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832593/ https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-021-00613-9 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095 https://www.karger.com/Article/FullText/353672 sci-hub.se/10.4149/BLL_2018_020 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314618/

If you have any information about Marshal's whereabouts, his disappearance, or have any video footage from November of 2019, please contact Crime Stoppers or Lethbridge Police. LETHBRIDGE POLICE: 403-328-4444 CRIME STOPPERS: 1-800-222-8477 or p3tips.com CASE #: 19030078 Marshal is 5 foot 11 inches, around 170 lbs, shoulder-length brown hair that he would tie back, and he had a mustache. He was last seen wearing a green hoodie, black pants, red hi-top sneakers, and a gray beanie. The license plate on his truck is BLL-1099     Watch the Youtube version (Sources in the Description) https://youtu.be/tQnwNxtUezs   Check out my website and submit cases www.danellehallantc.com   Follow my socials! facebook.com/danellehallan Instagram.com/danellehallanyt https://www.tiktok.com/@danellehallan

The Flying Theatre is the world's first theatre in an international airport (BLL) under the direction of Giuseppe L. Bonifati and creative producer Linda Sugataghy. Alongside the artistic activity, they have taught theatre and performance in drama schools and universities in Europe and America, and took part in various movies for cinema, television, alongside world-famous Hollywood stars and directors. www.detflyvendeteater.dk  www.lovefly.co.uk/courses/ Facebook 'Lovefly' Instagram @loveflyhelp  YouTube @loveflyteam   Intro music 'Fearless' by Daniel King #fearofflying #lovefly #flyingwithoutfear #virgin

About Our GuestCandice Fortman is the Executive Director at Outlier Media. She has worked in commercial and non-profit media, leading marketing, engagement, and growth strategy. Candice is a skilled manager with more than fifteen years of experience in team leadership. As the Executive Director of Outlier Media in Detroit, she helps to drive the work of Outliers mission which includes building a sustainable newsroom that challenges traditional models by centering the highest information needs of Detroiters. Before joining Outlier, Candice was the Marketing and Engagement Manager at WDET 101.9 Detroit's NPR station. Fortman is a 2021 alumna of the JSK fellowship at Stanford, where she studied how the business model of journalism impacts low-wealth communities.Aside from her duties at Outlier, Candice is also the host of News Guest, a podcast produced by LION (Local Independent Online News) Publishers that explores newsroom sustainability. Fortman sits on the board of Cityside, which operates Berkleyside and The Oaklandside in California. She is also an advisory board member for OpenNews, which connects developers, designers, journalists, and editors to collaborate on open technologies and processes within journalism.About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

Co-owner of Beauty Lab and Laser, Dre Robinson, joins Rosanna for a HUGE episode where she gives us all of the BRAND NEW inside  scoop on the lawsuit between BLL and Monica. This podcast is the first place to hear the big recent update that just happened this week on The Real Housewives of Salt Lake City! We also get Dre's hot takes on part 1 and part 2 of the reunion! 

About Our GuestJane Barrett has worked in journalism and at Reuters for more than 20 years but jokes that she has had five careers in that time. Her passion is to lead people positively through change and has been at the forefront of some of the industry battles through digital disruption and transformation. She's currently the Global Editor for Media News Strategy at Reuters where she has led several waves of digital transformation. As part of the Editorial leadership team, she now has responsibility for editorial innovation and new business, including AI, audio, fact-checking and events. She also works closely with Reuters global media clients to improve the agency's output and modernise journalistic formats and content.Previously, Jane led a huge multimedia transformation of global newsroom to better serve clients and consumers in a digital age. She has also been the business editor for EMEA, started up a financial video service and was a reporter in Italy and Spain. Outside Reuters she is a trustee of Podium.me, a charity that gets young people into journalism and storytelling through podcasts, and is a board member of the World Editors' Forum.About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

In today's episode Leanne and Chelle chat their way through everything written by Liane Moriaty, bestselling Australian Fiction author. Leanne and Chelle love a good plot twist and Liane Moriaty is masterful as blindsiding her audience. The Books: Nine Perfect Strangers Apple's Never Fall Big Little Lies What Alice Forgot The Husband's Secret Truly Madly Guilty Other Mentions: Big Little Lies and Nine Perfect Strangers were both turned into a made for tv mini series although BLL was extended into a 2 season mini series. Liane also wrote The Hypnotist's Love Story; The Last Anniversary; and, Three Wishes. Jaclyn Moriaty writes fiction for young readers. Nicola Moriaty, the youngest sister, wrote The Fifth Letter which Chelle referred to which is general fiction and had her captivated too. Leanne and Chelle wondered which other books of Lianne's have been optioned. We have since found an article dated 2017 that stating that What Alice Forgot; The Husband's Secret; and, Truly Madly Guilty had all been optioned. Further investigation revealed that Truly Madly Guilty is in development. It appears on IMDB that The Hypnotist's Love Story was released in 2019 starring Heather Graham and Jane Seymour however it only shows that there is one episode so may have had production stalled through the pandemic. Remember to keep reading and we'll see you Between The Lines.

About Our GuestGianpiero Petriglieri is Associate Professor of Organisational Behaviour at INSEAD and an expert on leadership and learning in the workplace. His award-winning research and teaching focus on what it means, and what it takes, to become a leader. He is particularly interested in the development and practice of leadership in the age of “nomadic professionalism,” an age in which people have deep  bonds to work but loose affiliations to organisations, and authenticity and mobility have replaced loyalty and advancement as hallmarks of virtue and success. All his work aspires to humanise leadership in this age, that is, to help leaders be grounded as well as as adaptable, sustainable as well as effective, purposeful as well as portable. That work has earned him a spot among the 50 most influential management thinkers in the world.A Medical Doctor and Psychiatrist by training, Gianpiero has worked as an executive coach, practiced as a psychotherapist, and served on the staff of group relations conferences in Europe and the United States. He has chaired the World Economic Forum's Global Agenda Council on new models of leadership, and has held Visiting Professor positions at the Harvard Business School, and at Copenhagen Business School.At INSEAD, Gianpiero directs the Management Acceleration Programme, the school's flagship executive programme for emerging leaders, and chairs the INSEAD initiative for Learning Innovation and Teaching Excellence. In the INSEAD MBA, he teaches the core course “Ethics: Value-based leadership for cosmopolitans,” for which he has received the Aspen Institute's  “Ideas worth Teaching“ award. He taught the “Leading People and Groups” core course for five years, receiving the students' Outstanding Teacher Award. He has earned numerous Dean's Commendations for Teaching Excellence in MBA and Executive Education.Gianpiero collaborates with multinationals in a variety of industries on the design and delivery of leadership development initiatives, some of which have received industry-wide awards for excellence and innovation in executive development. An insightful and engaging speaker, he presents widely at management conferences and corporate gatherings on how to live, lead, and learn “on the move” without losing one's roots.His research has appeared in leading academic journals, as well as  a range of media including the BBC, Der Spiegel, Financial Times, The Economist, The Guardian, New York Times, Time, Wall Street Journal, Washington Post, Le Figaro, and El Pais.About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

About Our Guest: Irving Washington dedicated his career to promoting diversity and encouraging media integrity within media organizations. As a Senior Fellow at KFF (formerly Kaiser Family Foundation), he leads a new initiative focused on identifying health misinformation to improve understanding of critical health news and research and build trust among communities. As the former CEO of the Online News Association (ONA) — the world's leading digital journalism association — Irving's leadership prioritized innovation in digital journalism. His commitment to representation and equity began from his impactful roles at both the National Association of Black Journalists and the Radio Television Digital News Foundation. With a career spanning more than two decades at the intersection of journalism, technology, and diversity, equity and inclusion, Irving's leadership continues to play a pivotal role in shaping a more inclusive and trustworthy media and technology landscape.About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

About Our Guest:Ros Atkins is a renowned BBC News presenter and newly appointed Analysis Editor. Since 2019, he has spearheaded a video explainer format that has become a global phenomenon with vast audiences on social media and on the BBC's digital, TV and radio channels. Ros has anchored coverage for many of the biggest global stories including Brexit, COVID-19, the war in Ukraine and multiple US and European elections and has reported from all over the world. In 2017, Ros founded the 50:50 Project. He started it to support diverse representation in the BBC's newsroom and it now works across all BBC content. The 50:50 Project has grown into a global initiative with over 130 organizations in over 30 countries taking part from a variety of sectors. In 2023, he released his book titled: “The Art of Explanation: How to Communicate with Clarity and Confidence” where he provides strategies to communicate effectively in any situation. About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

About Our Guest: Reneé Kaplan, the incoming Director of News at European news channel ARTE, is a highly experienced digital media transformation expert.Before joining ARTE, Renée was the Head of digital editorial development at the Financial Times, where she lead teams working on innovation, new editorial products and much of the FT's digital journalism, including newsletters and podcasts. She also focused on new forms of distribution, and new ways to monetize digital journalism.Before coming to the Financial Times, she was Deputy Editorial Director of news network France 24, and has worked as a journalist on staff at numerous U.S. media including CNN, CBS and the New York Observer. She is Franco-American and lives in London.About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

About Our Guest:Raju Narisetti's current role as Leader, Global Publishing at McKinsey & Company, is the latest in a 33-year global career in media and publishing, during which he has created, reimagined and managed major media organizations in North America, Europe and Asia, as well as led from the front in the digital transformation challenges and new ventures in publishing. Raju began as a journalist at The Wall Street Journal where, over 14 years, he went from a Reporting Intern to be the Editor of WSJ Europe, and later Managing Editor — Digital, of the global WSJ, and part of a team that won the 2002 Pulitzer Prize for Breaking News for 9/11 coverage. At The Washington Post, Raju was the Managing Editor who helped start and shape the newspaper's print/digital transformation. At both WSJ and Washington Post, Raju was the youngest and first person of color in a leadership role. Raju is also the founder of Mint, a national business newspaper and website in India. After his journalism stint, as a media business executive, he was Senior Vice President of Strategy for News Corp, and later CEO of the Gizmodo Media Group, which then encompassed a group of digital journalism sites that included Gizmodo, The Onion, Jezebel, DeadSpin, Lifehacker, and The Root. Prior to joining McKinsey in January 2020, he was a journalism educator, leading the Knight Bagehot Fellowships in Economics and Business Journalism at Columbia University, where he also was a Professor of Professional Practice at the School of Journalism. About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

About Our Guest:Before joining AP in 2014 as its Global Business Editor, Lisa Gibbs spent the majority of her career working as a business journalist, which includes a 5 year period as Executive Business Editor of the Miami Herald. After moving to AP and working as the Business Editor, AP soon launched its first ever large scale automation project which turned corporate earnings data into thousands of automatically generated stories. This initiative led to Lisa's involvement in AP's artificial intelligence strategy group to explore the ways news organizations can better leverage technology to deliver more impactful journalism. In addition to technological advancements, Lisa is fascinated by the power of collaboration as a way to grow and strengthen a resource-stretched newsroom. This fascination acted as a springboard for her new role as director of news partnerships in understanding the role of philanthropic foundations and how they can support innovation. Today, Lisa's team oversees funding from more than 22 philanthropies that helps AP deliver impactful journalism and news industry support.About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

Laura from the “Why the Book Wins” YouTube channel and podcast joins the show to help Luke & James finish out both the book by Liane Moriarty and show by Jean-Marc Vallée and David E. Kelley. In episode 274, they discuss the second half of the novel and episodes 5, 6, and 7 of the show. Topics include: what Ed would hate about podcast analysis, where BLL ranks among other Liane Moriarty books, how the cast brings it home (Nicole Kidman, Zoë Kravitz, Reese Witherspoon, Laura Dern, Shailene Woodley, Alexander Skarsgård, Adam Scott), what Luke predicted correctly and what he got spectacularly wrong, and they finish by each casting their votes for which was better: the book or the TV show! Why the Book Wins Podcast https://whythebookwins.com/listen-to-podcast/ YouTube https://www.youtube.com/c/WhytheBookWins Instagram https://www.instagram.com/whythebookwins/ Ink to Film Purchase Big Little Lies or any of the other source books or guest novels at Ink to Film's bookshop: www.bookshop.org/shop/inktofilm Ink to Film's Twitter, Facebook, Instagram (@inktofilm) Home Base: inktofilm.com Intro Music: “Black Fingerprint” by Dylan Owen https://www.youtube.com/watch?v=Uk5zngU-aAE&t=0s Luke Elliott Website: www.lukeelliottauthor.com Twitter: https://twitter.com/luminousluke IG: https://www.instagram.com/lpelliott/ Mastodon: https://wandering.shop/@LuminousLuke James Bailey Twitter: https://twitter.com/Jame_Bail

About Our Guest: Shazna Nessa is the global head of visuals at The Wall Street Journal.  In this masthead position she is responsible for unique digital experiences and the visual journalism that is created daily by journalists with specialized skills in areas such as data visualization, photography, cartography, 3D, design, and illustration, across multiple platforms.Prior roles include positions at The Knight Foundation, The Associated Press, and Condé Nast. She was the President of the Board of Directors for the Online News Association 2020-2022, and was a Board Advisor for the Tow Center for Digital Journalism at Columbia University, as well as the Journalism and Design program at the New School.Shazna was born and raised in London's East End and holds a bachelor's degree from the Sorbonne, Paris. She was a 2008 Sulzberger fellow at Columbia University and a 2014 John S. Knight journalism fellow at Stanford University.About Your Host: Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

About Our Guest: Federica Cherubini is the Director of Leadership Development at the Reuters Institute for the Study of Journalism. She is an expert in newsroom operations and organizational change, with ten years experience spanning major publishers, research institutes and editorial networks around the world.Before working at the Reuters Institute, she worked as a consultant to develop a more inclusive, sustainable, and communicative work environment at Hearken. However, she began her development journey at Condé Nast International where she worked in outreach and found her passion for personal and professional growth. Apart from being passionate about development and growth, she works hard in engaging with organizations at all levels to spread awareness for the importance of diversity and inclusivity, and build bridges between the gap between senior management and often younger workers, whose values of what it means to work have changed. About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders Lab:Better Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.comYou can also find us at Twitter, Instagram, LinkedIn, and now YouTube!

Pride month going strong here at BLL! Heather Gay is full of quippy, witty Pride quotes, courtesy of a mass email she received. But why do two straight girls love to celebrate Pride? Parker from TeamBLL is here to SCHOOL us on why it's important as people and as a business to join in the love. #TheLabLovesYOU

About Our Guest:Styli Charalambous co-founded the Daily Maverick in 2009, while navigating massive industry disruption and South Africas turbulent politics.As founding CEO and publisher, Styli helped grow Daily Maverick from a 5 person start-up to now more than 100 full-time staff, reaching 9 Million monthly unique visitors with 20.000 voluntary paying members.He is passionate about leadership and innovation focusing on new revenue models, product, technology and membership in news. In 2021, he was awarded South Africa's top journalism award for courage and integrity for his shaping role in Daily Maverick's success.About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com

About Our Guest:Graciela Mochkofsky is the dean at CUNY's Craig Newmark Graduate School of Journalism, where she was previously the executive director of its Center for Community Media, and founding director of its Bilingual Journalism Program. The Newmark Graduate School of Journalism is located in Midtown Manhattan. It's the only public J-School in the Northeastern U.S. and is dedicated to training a diverse and innovative generation of journalists.Graciela is a contributing writer for The New Yorker, and the author of seven books of nonfiction, including “The Prophet of the Andes: An Unlikely Journey to the Promised Land” (Knopf, 2022.) She is a native of Argentina and a recipient of the Maria Moors Cabot Prize for outstanding reporting across the Americas.About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com

About Our Guest:Rafat Ali is the CEO & Founder of Skift, the most influential business media & information company in the travel industry, providing news, research, events, and creative services to key stakeholders globally.Previously, he was the founder/CEO of paidContent and ContentNext, which he sold to UK's Guardian News and Media in 2008, and left in 2010. Prior to that, he was managing editor of Silicon Alley Reporter. Rafat was the Knight Fellow at Indiana University, where he completed his Masters in Journalism, 1999-2000. Prior to that he completed his BSc in Computer Engineering, from AMU in Aligarh, India.About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com

About Our Guest:Paul Cheung leads The Center for Public Integrity, one of the oldest and most diverse investigative nonprofit news organizations in America, as CEO to hold the powerful to account, expose systems of inequality and equip the public with knowledge to drive change. Their reporting has led to hundreds of law and policy changes and forced federal and state governments to release information critical to the public interest.Previously, Cheung managed a $50 million dollar investment portfolio at the Knight Foundation to scale AI, business sustainability solutions, and mitigating misinformation. He has 20 years of experience in leading digital transformation at media outlets including NBC News Digital, The Associated Press, The Miami Herald, and The Wall Street Journal.Cheung serves on the boards of Center for Disaster Philanthropy and News Leaders Association. He is a Council member of University of Florida's Consortium on Trust in Media and Technology and co-leads the Asian American Journalists Association's executive leadership program in US and Asia. Cheung is a graduate of the 2016 Punch Sulzberger Executive Leadership program at Columbia University and an alumnus of New York University.About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and smart management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com

About Our Guest:Hillary Frey is the editor in chief of Slate Magazine, an audio and online destination for smart analysis of news and culture, and the home of Dear Prudence and myriad advice columns. Before joining Slate in June 2021, Hillary was a creator in residence at the Newmark School of Journalism at CUNY, and a graduate of the school's Executive Program in News Innovation and Leadership. Previously she was executive editor of HuffPost, editorial director of news at NBCNews.com, and media and culture editor at the New York Observer (among other things!). She began her career in the late '90s in the advertising department of the tiny, award-winning magazine Lingua Franca. From there, she moved through editing roles initially focused on culture (The Nation, Salon.com), media (The New York Observer, Politico) and then into news (Adweek, Yahoo News, NBC News, and Fusion). Over the past decade, leading newsrooms large and small, she has focused on empathetic management, improving development processes, and building healthy culture, as well as collaborative processes with unionized teams. She lives in Brooklyn with her daughter.About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and strategic management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com

About Our GuestIn Upasna's role as Product Manager on the Digital News Platforms team at CNN, she works with CNN's engineers, designers, editors, and journalists to develop and optimize the content management technology that delivers breaking news to the world. Upasna has been working in the tech industry for the last 15 years, where she has been an integral part of delivering technical, data-informed solutions for brands such as Ford Motor Company, Valvoline, PCMag, Mashable, Mars Corporation, and Kimberly-Clark.Outside of her day job at CNN, Upasna is an avid public speaker, tech career coach, meditation teacher, and a Community Lead with Google's Women Techmakers. In 2022, Upasna was awarded a Top Product Coach honor by Reforge. Upasna was recently appointed to the News Product Alliance Board of Directors and is excited to serve her first term in March.About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship. About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and strategic management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com

About Our Guest:Sara Weber, born in 1987, is a journalist, bestselling author, and digital strategist. She majored in journalism and book science and graduated from Germany's oldest journalism school Deutsche Journalistenschule. She worked as a freelance writer for Zeit, Süddeutsche Zeitung and Spiegel, among others. As Senior Managing Editor of LinkedIn, she was the face of the network in Germany until she quit her job in 2021. Her main topics are the future of work, business and digitization. She just published her book: "The world is ending and I still have to work?" - exploring how multiple crises impact a generation that is questioning if work is everything and is aiming to rethink the way we work. The German-American lives in Munich. About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship.About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and strategic management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com 

About Our Guest:Trei Brundrett is a co-founder and the former Chief Operating Officer of Vox Media, where he oversaw the highest priority cross-company initiatives and directed the Design, Technology and Product groups. He now provides strategic leadership, media and technology consulting services to investment firms, media companies and non-profit organizations.At Vox Media, he led the team responsible for developing Chorus, Vox Media's modern media platform designed from the ground up to launch premium digital media brands and deliver content and community. Trei was instrumental in growing Vox Media from a collection of sports blogs to a ground-breaking media organization with a portfolio of leading brands including SB Nation, The Verge, Polygon, Eater, Curbed, Vox, Recode, New York Magazine, Vulture, The Cut, GrubStreet, NowThisNews, Thrillist, The Dodo, and PopSugar. He was named to The AdWeek 50, which wrote, "Under Brundrett's direction, Vox Media has evolved into one of the most agile Web-based publishers."Previously, as the co-founder of the boutique digital strategy firm Handwire, Trei led large-scale internet strategy, advertising and development projects for Fortune 500 companies, national non-profits and media clients such as Microsoft XBOX, MD Anderson Cancer Center, Royal Dutch Shell, and Texas Monthly. Trei also led the digital technology and strategy efforts for Senator Mark Warner's 2008 presidential bid.He serves as the Vice Chair on the board of The Texas Tribune, co-chairs the philanthropy committee of The McDonald Observatory Board of Visitors and is an advisor to OpenNews. He studied History and Astronomy at the University of North Carolina at Greensboro. He lives in Montclair, NJ with his wife, four children and their dog, Lucy.About Your Host:Anita Zielina is the CEO and founder of Better Leaders Lab. She's also an Executive in Residence at the Craig Newmark Graduate School of Journalism at CUNY, where she spent the last few years leading all continuing and executive education initiatives. Anita serves as the inaugural Board Chair of News Product Alliance (NPA) and is a member of the board of directors at the Austrian Public Broadcaster ORF.For the past 15 years, Anita held senior executive positions focused on product, strategy and innovation in various media and education organizations as Chief Product Officer, Managing Editor Digital, Editor-in-Chief and Director Strategic Initiatives. She has worked with around 500 managers, leaders and entrepreneurs as a consultant, coach and educator.She holds a Master in Law from Vienna University and an Executive MBA from INSEAD. Anita is an alumna of the Stanford Knight Journalism Fellowship and the Oxford Reuters Institute Fellowship.About Better Leaders LabBetter Leaders Lab is a Do and Think Tank for good leadership and strategic management in media and beyond and a boutique strategic advisory firm. BLL specializes in organizational change, strategy and scenario planning, leadership development and executive recruiting research. Its goal is to empower managers, leaders and organizations in the broader media, digital & innovation space to build successful, sustainable, modern and healthy businesses.Learn more:https://betterleaderslab.comGet in touchFeedback or questions related to the podcast?hello@betterleaderslab.com 

Today's guest is  Ariana Makau of Nzilani Glass. She is the 2nd person in the world – and the first woman – to receive a Master's Degree in Stained Glass Conservation from the Royal College of Art in London. Equally comfortable on a job site, at a board meeting or in a museum, Makau has over 25 years of experience with art and architectural preservation.  She is a Board Member and Health and Safety Chair of the SGAA and is a Fellow of AIC. Before Nzilani, she worked at the J. Paul Getty Museum in LA, London's V&A Museum, and the NY  Metropolitan Museum of Art.  Approachable and non-judgmental, Ariana enjoys sharing her professional experience in classroom and public talks.  I could have spoken to Ariana for 2 more hrs and still only scratched the surface of her extensive experience and knowledge of glass conservation and preservation. Asbestos testing /Respirator fit tests-Ariana recommends you do a local search with the key words "asbestos material testing company" and "respirator fit tests".  In some cases, people might be able to get the latter sourced through a museum.  Local paint companies sometimes teach one day lead certification classes as well."Nzilani is hoping to roll out hosting contracted respirator fit and BLL testing next year as a service to local artists. I encourage individual artists to network and do the same in their areas. Joining together can reduce costs, build community and empower folks to be accountable to their own health and well-being."-Ariana Makaucascademetals.com Ted Sawyer- Bullseye lead scientistbullseyeprojects.comTyvek Suitpksafety.comHope Crewsavingplaces.org/hope-crewConservation Schools:Buffalo State University Art Conservation DepartmentWinterthur UD Program in Art ConservationNYU ConservationUCLA/Getty Interdepartmental Program James Turrelljamesturrell.comLiza Enebeis @bookslovelizaEmily AtefwikipediaCyril Atef@cyrilatefOctavia E. ButlerwikipediaGlass artists:Harry ClarkwikipediaThe Stained Glass Association of America The Professional Trade Association for Architectural Art GlassPaul Wissmach Glass Co. Your Source of Colored Sheet GlassCanfield Technologies Canfield sets the standard for the Stained Glass industry. Support the show

In this 3rd installment into the series Rob and Bll look at Djent, Modern Metalcore, Industrial Rock & Metal, and Black Metal. Who makes it in?Check out other shows from the network: https://www.theden.show/Check out the website: metalheadjourneys.com

Gerard joins Breakfast with Vossy and James Magnussen

Il fait chaud, on rêve de grandes étendues d'eau et de tranquillité, d'être dorlotés, de dépaysement globalement. The White Lotus sur OCS Considérée par beaucoup dont notre propre équipe comme l'une des révélations de l'année dernière, The White Lotus de HBO voit son intrigue se dérouler nulle autre part que Hawaï. Passez une semaine dans un resort de luxe sur l'île pour des vacances pas si paradisiaques. Les premières minutes de la saison en 6 épisodes nous l'expliquent, il y a eu une mort. Mais comment, qui, quoi ? On va le découvrir au fur et à mesure avec un groupe de touristes tous plus frustrants les uns que les autres tout comme certains employés de l'hôtel. https://youtu.be/ObwYG3aOcgU L'ambiance de The White Lotus reflète très bien la série. Sous des airs parfaits, le ton s'assombrit pour partir en cauchemar sous psychédéliques. Au-delà de sa force d'écriture, l'ensemble d'acteurs est tout simplement brillant. Pour donner une idée, sur les six nommées de la catégorie meilleure actrice secondaire quatre proviennent de The White Lotus. On adore détester tous ces personnages qui ne devraient pas se plaindre autant ou avoir autant de problèmes, on les jalouse et on ne peut pas s'empêcher de les juger. Mike White a su créer une anthologie bien ficelée et il renouvellera l'expérience en Italie pour la saison 2. Nine Perfect Strangers Pourquoi ne pas partir en retraite déconnectée pour vous ressourcer ? C'est ce que proposent David E. Kelley qui rembauche Nicole Kidman après Big Little Lies pour sa mini-série où neuf étrangers rejoignent une retraite spirituelle. Et ça tome bien puisqu'il s'agit d'une autre adaptation d'un roman de Liane Moriarty, l'autrice de BLL. Dans Nine Perfect Strangers, ils vont devoir se confronter à leurs passés et surtout à eux-mêmes pour en ressortir changés. https://youtu.be/ouZtyEUI2ak Bizarre et dérangeant, la série joue avec l'aspect huis-clos avec ce décor mystérieux coupé du monde où des tempéraments qui semblent dangereux cohabitent. Entre des secrets bien gardés et des situations étonnantes, il manque certainement un peu d'ambition narrative dans la série pour aller plus loin qu'un produit bien léché avec un casting cinq étoiles. La promesse implicite reste en tout cas intéressante n'est jamais complètement atteinte. Acapulco Acapulco fait peu parler d'elle et pourtant c'est bien l'une des comédies qui fait son petit bout de chemin sur Apple TV+. Alors que la saison 2 ne devrait pas tarder, laissez-vous tenter par l'adaptation en série de How To Be A Latin Lover, le film de 2017. Eugenio Derbez reprend son rôle et vient raconter comment son personnage sorti des rues pauvres d'Acapulco a réussi à grimper les échelons. Tantôt en anglais, tantôt en espagnol, l'histoire touchante d'un rêve américain pourra peut-être vous convaincre dans ce Mexique des années 80 pleine de couleurs. https://youtu.be/e8YKi_05emo Cette comédie ne cherche pas à prouver quelque chose mais existe pour tenter de rajouter un peu de douceur et de soleil dans vos vies. Découvrez simplement la ville mexicaine comme vous ne l'avez jamais vue avec son hôtel Las Colinas pour un voyage feel good. Loin de l'humour de front d'une sitcom, il y a pourtant de véritables moments humoristiques doublés d'émotions dans Acapulco. Alors, une destination favorite pour cet été ?

Il fait chaud, on rêve de grandes étendues d'eau et de tranquillité, d'être dorlotés, de dépaysement globalement. The White Lotus sur OCS Considérée par beaucoup dont notre propre équipe comme l'une des révélations de l'année dernière, The White Lotus de HBO voit son intrigue se dérouler nulle autre part que Hawaï. Passez une semaine dans un resort de luxe sur l'île pour des vacances pas si paradisiaques. Les premières minutes de la saison en 6 épisodes nous l'expliquent, il y a eu une mort. Mais comment, qui, quoi ? On va le découvrir au fur et à mesure avec un groupe de touristes tous plus frustrants les uns que les autres tout comme certains employés de l'hôtel. https://youtu.be/ObwYG3aOcgU L'ambiance de The White Lotus reflète très bien la série. Sous des airs parfaits, le ton s'assombrit pour partir en cauchemar sous psychédéliques. Au-delà de sa force d'écriture, l'ensemble d'acteurs est tout simplement brillant. Pour donner une idée, sur les six nommées de la catégorie meilleure actrice secondaire quatre proviennent de The White Lotus. On adore détester tous ces personnages qui ne devraient pas se plaindre autant ou avoir autant de problèmes, on les jalouse et on ne peut pas s'empêcher de les juger. Mike White a su créer une anthologie bien ficelée et il renouvellera l'expérience en Italie pour la saison 2. Nine Perfect Strangers Pourquoi ne pas partir en retraite déconnectée pour vous ressourcer ? C'est ce que proposent David E. Kelley qui rembauche Nicole Kidman après Big Little Lies pour sa mini-série où neuf étrangers rejoignent une retraite spirituelle. Et ça tome bien puisqu'il s'agit d'une autre adaptation d'un roman de Liane Moriarty, l'autrice de BLL. Dans Nine Perfect Strangers, ils vont devoir se confronter à leurs passés et surtout à eux-mêmes pour en ressortir changés. https://youtu.be/ouZtyEUI2ak Bizarre et dérangeant, la série joue avec l'aspect huis-clos avec ce décor mystérieux coupé du monde où des tempéraments qui semblent dangereux cohabitent. Entre des secrets bien gardés et des situations étonnantes, il manque certainement un peu d'ambition narrative dans la série pour aller plus loin qu'un produit bien léché avec un casting cinq étoiles. La promesse implicite reste en tout cas intéressante n'est jamais complètement atteinte. Acapulco Acapulco fait peu parler d'elle et pourtant c'est bien l'une des comédies qui fait son petit bout de chemin sur Apple TV+. Alors que la saison 2 ne devrait pas tarder, laissez-vous tenter par l'adaptation en série de How To Be A Latin Lover, le film de 2017. Eugenio Derbez reprend son rôle et vient raconter comment son personnage sorti des rues pauvres d'Acapulco a réussi à grimper les échelons. Tantôt en anglais, tantôt en espagnol, l'histoire touchante d'un rêve américain pourra peut-être vous convaincre dans ce Mexique des années 80 pleine de couleurs. https://youtu.be/e8YKi_05emo Cette comédie ne cherche pas à prouver quelque chose mais existe pour tenter de rajouter un peu de douceur et de soleil dans vos vies. Découvrez simplement la ville mexicaine comme vous ne l'avez jamais vue avec son hôtel Las Colinas pour un voyage feel good. Loin de l'humour de front d'une sitcom, il y a pourtant de véritables moments humoristiques doublés d'émotions dans Acapulco. Alors, une destination favorite pour cet été ?

Today Tyler joined by Tom Philips who can't wait to be inducted into our cult… er… crew, here at BLL.  He is an author, Screenwriter, video editor, Dungeons and Dragons Player. Who has just started the presale of his latest book, The Curious League of Detectives and Thieves 1: Egypt's Fire. Tyler was so excited to be chatting with such a cool guy, and hopefully he doesn't through the thin vale of our indoctrination ritual. You can find his presale going on right now until June 2022:  https://www.penguinrandomhouse.com/books/703135/the-curious-league-of-detectives-and-thieves-1-egypts-fire-by-by-tom-phillips/   Thank you to Jake Bassen for our theme song: https://soundcloud.com/jakebassen   As well as Cam Clawson, for our Correspondence Remix: https://soundcloud.com/camclawson7   Follow us on Instagram: @lewisandlovecraft   Tyler is @twclawson_pdx   Hannah is @thehannahray   Facebook: https://www.facebook.com/LewisandLovecraft/   Website: https://lewislovecraft.weebly.com/   Email: lewisandlovecraft@gmail.com

Alles über meine BLL (besondere Lernleistung) und die Frage ob ihr auch eine machen solltet...

Lou Whiteman joins the show as we answer a question from the listener mailbag and take a look at 3 under-the-radar aerospace stocks Stocks Mentioned: HWM, BLL, HEI, TDG, BRK.A, BRK.B, HXL Check out more of our content here: Podcasts Youtube Twitter Reach us by Email @ IndustryFocus@fool.com

Become a PatronThe guys finally decide to work together, and add an additional civilian to the crew (Head-Space), but on top of new friendships comes NEW WEAPONS. After the bright eyes brought on by the the new "stabby-stabby" devices made, the guys get into the heart of BLL's research. a small obsidian egg with a fleshy membrane holding it together. Whatever it is Frank wants to know, and it seems like he'll go through any means to find out. Sonny, and Miles finally make their way to the security room and devise themselves a plan to lift the security lockdown, but will it be enough? will everyone survive? and of the people who do... will they ever be the same? SOCIAL MEDIA:  The Amateur HourGAME RECOGNITION: Published by arrangement with the Delta Green Partnership. The intellectual property known as Delta Green is a trademark and copyright owned by the Delta Green Partnership, who has licensed its use here. The contents of this document are ©The Amateur Hour Podcast, excepting those elements that are components of the Delta Green intellectual property. SOUND CREDITS: SFX: Videvo_TelephoneElectron 1025_59_3Videvo_AnsweringMachine 6028_14_1MUSIC: Videvo_In-Harms-Way-FFT011401Videvo_Unending-Horror-FFT012301Videvo_Tubular-DHT012201Videvo_Suspended-SNS010601Videvo_Light-the-Fuse_FULL_EMM011701Videvo_Running-Out-of-Room-FFT012401Intro/Outro: Polaroid by pastis EDITED BY: Kyle and Vance--- Support this podcast: https://anchor.fm/amateurpod/supportSupport the show (https://www.patreon.com/theamateurhour)

The theme of stagnation with rising raw material prices continues to plague the future, says Michele “Mish” Schneider, Director of Trader Education and Research at MarketGuage.com. She talks about her three stock picks which include U.S. Steel (X), Marathon Digital (MARA), Ball Corp. (BLL), and Palantir (PLTR). She also discusses S&P 500 leaders and laggards. Tune in to find out more.

This episode with Travis Berwald (The Retail Butcher) wraps up season one of 'The Meat Up'. Travis talks to us about the beginning of Butchers Lounge Live (BLL), how it all came together and explains how both BLL and Instagram  have changed the way he learns within the industry. Travis is a super humble bloke and a great ambassador for our industry. Instagram - @theretailbutcher@butchers_lounge_liveIntro & Outro SongInstant Coffee by BugsThe Meat Up Instagram - @themeatup_podcast Support the show (https://www.lukeleyson.com/shop)

Nobel Prize for Silence, Potent Imagineering, BLL, Planetaires, People from the Future League, Horny Eyed EagleListen and subscribe to our new show THE POP TEST on Radio National or as a PodcastAnd buy tickets to TELEPORT at the Melbourne International Comedy Festival 2021Join the other TITTT scholars on the TITTT discord server hereGet Magma here: https://sospresents.com/programs/magmaHey, why not listen to Al's meditation/comedy podcast ShusherDon't forget TITTT Merch is now available on Red Bubble. Head over here and grab yourselves some material objects...and you can support the pod by chipping in to our patreon here (thank you!)You can find us on twitter at @twointankAndy Matthews: @stupidoldandyAlasdair Tremblay-Birchall: @alasdairtb and instaAnd you can find us on the Facebook right hereAuthentic denim thanks to George for producing this episode. See acast.com/privacy for privacy and opt-out information.

Discover how to quickly reverse insulin resistance. You'll learn what is insulin resistance, how insulin works, the 5 best foods for insulin sensitivity, and how to overcome a blood sugar problem. Insulin resistance can be reversed. Whether you are dealing with prediabetes, diabetes or full blown insulin resistance; this video provides 5 easy tips to reverse insulin resistance. / / E P I S O D E   S P ON S O R S  PureForm Omega Plant Based Oils (Best Alternative to Fish Oil): http://www.purelifescience.com Use ben4 for $4.00 off. Dr Phillips CBD oil, CBD gummies, CBD topical pain cream. Use keto15 for 15% off: https://www.drphillipscbd.com/ketokamp Free Keto Masterclass: http://www.ketosismasterclass.com 00:38​ What is insulin resistance 02:19​ Remove these inflammatory vegetable oils. Western diets consisting of high level of omega-6 fatty acids (predominantly from corn, sunflower, safflower, soybean oil) and sugar in the form of fructose play a key role in the development of MetS which include insulin resistance/impaired glucose tolerance Omega-3 deficiency and associated health issues a result of modern agriculture focused on increased production of vegetable oils https://www.ncbi.nlm.nih.gov/pmc/arti...​ Study replaced 80% of fish oil fed to Atlantic salmon with different vegetable oils: rapeseed, olive, or soy bean. Soybean oil particularly lowered omega-3 and increased omega-6 PUFA levels in salmon and in mice blood samples; Also increased insulin resistance and fat in the liver https://www.ncbi.nlm.nih.gov/pmc/arti...​ https://jeb.biologists.org/content/22...​ 03:25​ The 5 best foods for insulin resistance Diet high in MUFA (i.e. olive oil, avocados, macadamia, etc.) may lead to improvements in IR (+ fat/weight loss) versus diets higher in SFAs Through increased fat oxidation rates SFA foods are also high in oleic acid, but olive oil higher Diet high in omega-6 PUFA may promote IR, inflammation, obesity versus diets higher in omega-3 PUFAs https://www.ncbi.nlm.nih.gov/pmc/arti...​ Olive oil promising for multiple health benefits include antidiabetic effects, and improving insulin sensitivity Improved diabetes related outcomes: glucose control, HbA1c, HOMA, reduced complications, reduced type 2 DM incidence https://www.ncbi.nlm.nih.gov/pmc/arti...​ https://www.ncbi.nlm.nih.gov/pmc/arti...​ https://www.ncbi.nlm.nih.gov/pmc/arti...​ My favorite olive oil: http://www.ketokampoliveoil.com​ 04:56​ Intermittent fasting for insulin resistance Intermittent fasting improves health through its benefits for weight loss. After 5 weeks of controlled diets, early time-restricted feeding resulted in improved insulin levels & sensitivity, beta cell responsiveness (+ blood pressure and levels of oxidative stress) among pre-diabetic men https://www.sciencedirect.com/science...​ Systematic review studying the effects of intermittent fasting diets in the general population found decreased BMI, fasting glucose levels, and HOMA-IR HOMA-IR reduction may be related to the ability of intermittent fasting diets to minimize loss of lean body mass, while reducing body fat https://www.ncbi.nlm.nih.gov/pmc/arti...​ 06:51​ Extended fasting Water-only fasting for 11 days, followed by ‘regeneration diet’ for 11 days Positive effects of water fasting included reduced oxidative stress, weight, BP sci-hub.se/10.4149/BLL_2018_020 Improvements included weight loss, reduced abdominal circumference, improved glucose parameters, ketosis https://www.ncbi.nlm.nih.gov/pmc/arti...​ Metabolic and Psychological response to 7-day fasting in obese patients with and without metabolic syndrome https://www.karger.com/Article/FullTe...​ 07:55​ Heavy metals I estimate that 33% of type 2 diabetes is from heavy metals. https://sci-hub.se/10.1016/j.envres.2...​ https://www.ncbi.nlm.nih.gov/pmc/arti...​ https://sci-hub.se/10.1016/j.jhazmat....​ https://www.ncbi.nlm.nih.gov/pmc/arti...​ Free Toxicity Quiz: http://www.toxicmiami.com​

Our guest on this episode of the DevReady Podcast is Jeremy Streten, founder of “Business Legal Life Cycle”, a business focused on making legal advice accessible to business owners. Jeremy briefly started out his career in IT before pivoting to become a lawyer about 17 years ago. After several years in the industry, Jeremy realized that many lawyers tend to speak with their clients in unnecessarily complicated ways that are not helpful to average people who do not have legal training. He saw an opportunity for building a bridge between business owners and helpful legal advice and he sought out a developer to help him create the infrastructure. The basis for the BLL assessment came from Jeremy's outline of the 13 business phases, which eventually became his book entitled “The Business Legal Life Cycle.” During the creation of the first version of the Business Legal Life Cycle software, Jeremy experienced plenty of miscommunications with the developer he had hired. This solidified in his mind the necessity for a tech partner and also for the implementation of proper documentation at the beginning of all client and employment relationships. When it came time to work on version 2.0, Jeremy reached out to a Mastermind group that he was a part of in the U.S. and met an interested developer there who eventually became his business partner. He says that having a tech partner continually involved in the business and the evolution of the tech being used is a crucial part of the business. Topics Covered: • Many lawyers aren't very helpful because they don't speak plain English to their clients. • How Jeremy's legal background helped prepare him to fill in this gap between business owners and proper legal advice. • Keeping in mind what you want to do in the future. • Setting up your documentation the right way from the start. • Finding the right developer and building out the tech. • How miscommunications can lead to misaligned expectations and outcomes. • Changing the targeting of the product based on feedback. • Having a larger purpose: to make legal advice accessible to business owners. Key Quotes • “It's to help business owners generally to know what they need to do from a legal perspective.” (1:10) • “People change. Money changes people.” (6:04) • “Every business evolves over time, and if you're not evolving then you're probably going backward.” (19:25) • “You get what you pay for.” (25:11)

SummaryLead is a dense elemental metal utilized by humans for possibly over 8,500 years. This toxic material has no known biological function in human physiology. It is particularly harmful to the brain, peripheral nervous system, blood, gastrointestinal tract, reproductive organs, mental health, and essentially every other major organ system. Morbidity and MortalityAt very high exposure levels (usually > 100 ug/dL BLL), lead can cause seizures, coma, and death via cerebral edema. However low levels of lead exposure (> 5 ug/dL BLL) over time are really the bigger concern. Even low levels of lead have been shown to lower IQ and cause behavioral disturbances. 815 million children worldwide are believed to have dangerously high lead levels, 500,000 a which reside in the United States. An estimated 900,000 adults are killed every year from lead poisoning. Worldwide, lead may account for as much as 1% of the global burden of disease. Story TimeRoman aristocratic society made a sweetener called sapa, a grape syrup simmered in lead containers. Many historians believe that extensive use of sapa, reduced the IQ of the ruling class, likely contributing to the fall of the empire. Before 1976 and 1978, lead was routinely added to gasoline and household paint in the United States. Blood lead levels (BLL) decreased from 12.8 ug/dL to 0.82 ug/dL over the 35 years following federal regulations banning lead additives in individuals age 1 to 74 years. This likely resulted in the average IQ increasing between 7 and 12 points. Key Points1. Children are at greatest risk for lead toxicity as they tend to put things in their mouth. Old houses with chipping lead paint are the greatest risk factor. Though blood lead levels have declined dramatically, the CDC and AAP still recommend routine screening in children.2. Occupational exposures are the greatest risk factor for lead poisoning in adults. Lead smelters, constructions workers, automotive radiator repairmen, firing range instructions, battery manufacturers, lead abatement workers, and metal workers are at greatest risk.3. The CDC has steadily decreased their definition of elevated blood levels from < 60 ug/dL to < 5 ug/dL over the past 60 years. There is no safe lead level.4. Blood lead levels are currently the best screening and diagnostic test for lead poisoning. Most lead is absorbed into the bone and can leach out into the body over decades. In the future, we will likely judge cumulative exposure by looking at bone lead levels.5. Removing the lead exposure is the most important treatment. At BLL > 45 in children and > 70 in adults, chelation therapy with substances like dimercaptal, CaNa2 EDTA, and succimer are both recommended and efficacious. References- Calello and Henretig. Ch. 93. Lead. Goldfranks Toxicology, 11th Ed. 2019- Burki. Report says 815 million children have high blood lead levels. Lancet. 2020.- Dignam, Kaufmann, LeStourgeon, & Brown. Control of Lead Sources in the United States, 1970-2017: Public Health Progress and Current Challenges to Eliminating Lead Exposure. Journal of public health management and practice. 2019.- Wikipedia: Lead, lead poisoning- WHO. Lead, Assessing the Environmental Burden of Disease. Available at: https://www.who.int/quantifying_ehimpacts/publications/9241546107/en/#:~:text=It%20is%20estimated%20that%20lead,exposure%20to%20lead%20is%20required.

What if Big Little Lies, but in New York City and with no point? That's kind of how Emily and the regulars all felt about The Undoing, the latest Nicole Kidman-David E. Kelley collaboration for HBO; we admired the workmanship, while not really understanding what sets it apart from BLL (besides the quality of the wigs), or buying Kidman and Hugh Grant's chemistry. Will any of us be successfully cliff-hung into watching all six episodes? Later, we investigated Around The Dial with stops at Archer, the new Supermarket Sweep, Revolutionary Girl Utena, The Morning Show, City So Real, and The Queen's Gambit, before location-scouting "Domestic Survivor" for Don's Extra Credit. Emily hoped the signal-to-noise ratio of a fourth-season Halt And Catch Fire episode would be good enough to connect it to the Canon. Stath Lets Flats won, Quibi lost, and Game Time proved a severe insult to the brain (and other things). Quick, look hunted! It's an all-new Extra Hot Great. GUESTS

What if Big Little Lies, but in New York City and with no point? That's kind of how Emily and the regulars all felt about The Undoing, the latest Nicole Kidman-David E. Kelley collaboration for HBO; we admired the workmanship, while not really understanding what sets it apart from BLL (besides the quality of the wigs), or buying Kidman and Hugh Grant's chemistry. Will any of us be successfully cliff-hung into watching all six episodes? Later, we investigated Around The Dial with stops at Archer, the new Supermarket Sweep, Revolutionary Girl Utena, The Morning Show, City So Real, and The Queen's Gambit, before location-scouting "Domestic Survivor" for Don's Extra Credit. Emily hoped the signal-to-noise ratio of a fourth-season Halt And Catch Fire episode would be good enough to connect it to the Canon. Stath Lets Flats won, Quibi lost, and Game Time proved a severe insult to the brain (and other things). Quick, look hunted! It's an all-new Extra Hot Great.SHOW TOPICSThe UndoingATD: ArcherATD: Supermarket SweepATD: Revolutionary Girl UtenaATD: The Morning ShowATD: City So RealExtra Credit: Domestic SurvivorThe Canon: Halt And Catch Fire S04.E02: Signal To NoiseWinner and Loser of the WeekGame Time: A Game For HoopleheadsSHOW NOTESEmily Yoshida on TwitterEmily's 2019 Hugh Grant profile for Vanity FairEmily's podcast, Night CallNight Call's Patreon pageTara on the premiere of The Conners for PrimetimerTara on SlashfilmcastSarah's "best of Kartemquin playlist" on Best EvidenceSeason Two of The Great American Pop Culture Quiz Show starts next week.Photo: Niko Tavernise / HBODISCUSSIONTweet at us @ExtraHotPodcast on TwitterWe are @ExtraHotGreat on InstagramSUPPORT EHG ON PATREONThe EHG gang have been recording this podcast for almost a decade now. In podcasting terms, that makes us positively Methuselahian. Since the start of EHG, our listeners have asked if we had a tip jar or donation system and we'd look at each other and say surely that is a joke, people don't pay other people to do podcasts. We'd email them back "Ha ha ha, good one, Chet" and go about our business. Now we are told this is a real thing that real nice people do. Value for value? In today's topsy turvy world? It's madness but that good kind of madness, like when you wake up at 3:15am and clean your... See acast.com/privacy for privacy and opt-out information.

Neurolinguistic Programming and other associated support methodologies have been of huge interest to so many in the Blue Light Leavers Private Facebook group and have proved incredibly helpful for many officers and their families within the BLL group! Rak Nathwani works with the individuals and families, the Police Firearms Officers Association, Police Federations, Police Mutual, numerous charities and the Mental Health Crisis Pathway.  In this interview, he talks about his own journey and the moment he broke and how NLP can help you and also gives some hints and tips on staying calm when the pressure's really on. You can connect with Rak via his fantastic website and see the testimonials via http://www.futurecreationassociates.co.uk/ If you're on shift and it's 'Q', have a listen! You can listen anywhere and whenever suits you best and they're all completely free!  Don't forget you can join our Private Facebook group at : www.facebook.com/groups/bluelightleavers You can also visit the website and blog on www.bluelightleavers.com Download my free guide to LinkedIn for Emergency Service Professionals via this link: https://www.bluelightleavers.com/pl/95723 If you like what you've heard, please subscribe, hit 5* and leave a review and share and come and join us in our Private Facebook Group. --- Send in a voice message: https://podcasters.spotify.com/pod/show/bluelightleavers/message

Nuevo estelar Tonka Tontas, update de Miley/Liam, ICONIC: Diana, personajes de BLL como signos del zodiaco